NCT04175132

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's Disease

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: H. Lundbeck A/S · Industry
• Sex: All
• Age: 50 Years – 70 Years
• Healthy volunteers: Accepted

Summary

A study to learn how foliglurax binds in regions of the brain

Detailed description

To study binding of foliglurax to mGlu4 receptors in human brain, up to 9 healthy subjects (Part A) and up to 8 patients with Parkinson's disease (Part B) will be injected with a liquid dose of a radiolabelled tracer that allows measurement of foliglurax binding in the brain to determine to which degree foliglurax binds to regions of the brain.

Conditions

• Healthy
• Parkinson Disease

Interventions

Type	Name	Description
DRUG	foliglurax	Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg
DRUG	foliglurax	Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg

Timeline

• Start date: 2019-11-12
• Primary completion: 2020-03-03
• Completion: 2020-03-10
• First posted: 2019-11-22
• Last updated: 2020-12-09

Locations

1 site across 1 country: Sweden